With over 30 years of combined experience and expertise in gene therapy and drug descovery
Company Founders
Co-Founder & CEO
Dr. Lucy Abgaryan, PhD, MBA
Dr. Abgaryan has more than 15 years of experience in the field of drug
discovery and small molecule pharmacology. Dr. Abgaryan had a track
record of 3 IND submissions, a number of PubChem molecular structure
discoveries and one FDA
-
approved drug, Ozanimod,
for treatment of
Multiple Sclerosis and Ulcerative Colitis. Throughout her career, she
developed multiple assays for high throughput drug screening and a
number of genetically modified cell lines as essential tools in drug
discovery. Dr. Abgaryan She is the invitro-pharmacologist for the lead discovery of drugs targeting KOR Antagonist and V1aR Antagonist receptors that are currently in clinical phases 2 and 1 in the pipeline.
She directly contributed to 7 start-ups and incubators from early-stage set-up, business development and market entry. i. Dr. Lucy Abgaryan has an undergraduate degree in physics and PhD in Biophysics from Yerevan State University, and an MBA from the University of California San Diego (UCSD). Dr. Abgaryan continues her education at The Scripps Research Institute as a postdoctoral fellow developing small molecule drugs for a number of disorders.
Co-Founder & CSO
Dr. Gor Sarkisyan, PhD
Dr. Gor Sarkisyan has more than 15 years of experience in developing in
vivo models for drug screening as second and third
-
phase drug
discovery pipelines. Dr. Sarkisyan has developed genetic modification
machinery for the development of n
ext
-
generation CAR
-
T
(reprogrammed patient
-
derived T cells to recognize and kill tumor cells
using the power of the patient’s own immune system) therapies for
cancer treatment including B cell lymphoma. Dr. Sarkisyan has a proven track record as a founding member with multidisciplinary startup ventures including optical communication in collaboration with the Navi as a co-founder or HSP as well as biomedical fields as a co-founder of Decano. Dr. Gor Sarkisyan has an undergraduate degree in biology from the University of San Diego and a PhD from Yerevan State University in biophysics. Dr. Sarkisyan continues his education at The Scripps Research Institute in the field of neuroscience as a postdoctoral fellow and later as a staff scientist in the field of drug discovery and genetic engineering for the treatment of cancer.
